Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Tofacitinib treatment for hair loss may worsen acne.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Baricitinib is effective and safe for treating severe alopecia areata.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Baricitinib may not always prevent relapse in alopecia areata.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

JAK inhibitors show promise for treating various skin diseases.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

ABCG2 protein marks stem-like skin cells in human epidermis.

Glibenclamide slows breast cancer cell growth by stopping cell division.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.